MGF

MGF is the mechanically inducible splice variant of the IGF-1 gene, designated IGF-1Ec in humans and IGF-1Eb in rodents. All IGF-1 splice variants share the mature IGF-1 region encoded by exons 3 and 4 but differ in their C-terminal "E-domain" extension; in MGF, inclusion of a short exon-5 insert (49 nucleotides in humans, 52 in rodents) shifts the reading frame in exon 6 to generate a distinct C-terminal peptide not found in the predominant systemic isoform IGF-1Ea. The foundational characterization came from Yang, Alnaqeeb, Simpson, and Goldspink (1996), who cloned a stretch-induced IGF-1 isoform from rabbit skeletal muscle using exon-specific probes and primers. McKoy and colleagues (1999) extended this in rabbit extensor digitorum longus with RNase protection assays, distinguishing the autocrine/paracrine MGF form from the liver-type IGF-1Ea under different mechanical signals. Goldspink's review (2005) synthesized the splicing model, and a growth-plate study by Schlegel and colleagues (2013) described the exon structure and the reading-frame shift in detail.

The most-cited cell-culture work is Yang and Goldspink (2002), who used a C2C12 myoblast model to examine the distinct E-domain peptide alongside mature IGF-1, contrasting proliferation and differentiation readouts and including an IGF-1R-blocking-antibody arm to probe receptor dependence. This framed a two-phase model in which preferential MGF splicing after mechanical loading is studied in relation to satellite-cell activation, with splicing later examined as it reverts toward IGF-1Ea. Human-tissue studies tested expression in vivo: Hameed and colleagues (2003) measured IGF-1 splice-variant mRNA in vastus lateralis biopsies from young and older men after high-resistance knee-extensor exercise, and Hameed and colleagues (2004) examined IGF-1 isoform mRNA with recombinant growth hormone and resistance training in elderly men. Primary-cell work includes Ates and colleagues (2007), who examined the splice variant in progenitor-cell cultures from ALS, dystrophic, and normal muscle donors, and Kandalla and colleagues (2011), who examined the 24-amino-acid E-peptide in human muscle progenitor cultures across donor ages, looking at proliferative lifespan, senescence timing, and fusion potential. Fornaro and colleagues (2014) examined the same peptide in myoblasts and primary muscle stem cells as part of the debate over whether it has independent activity.

A central, unresolved question is whether the E-peptide acts through the type-1 IGF-1 receptor (IGF-1R) or through a separate receptor. The mature IGF-1 region common to all isoforms signals through IGF-1R, a receptor tyrosine kinase coupled to the Raf-MEK-ERK and PI3K-Akt pathways. Yang and Goldspink (2002) examined the E-domain peptide in the presence of an IGF-1R-blocking antibody, a design interpreted as pointing toward a distinct receptor. Brisson and Barton (2012) took the opposing approach, using synthetic EA, EB, and scrambled-control peptides in C2C12 cells with MAPK/ERK readouts and a pharmacologic IGF-1R-inhibited arm to test whether E-peptide activity depends on IGF-1R; their review (2013) laid out the synthesis position that no E-peptide-specific receptor or binding partner has been identified. As Matheny, Nindl, and Adamo (2010) noted in their review, no analogous peptide product of the IGF-1 gene had been isolated from cells, conditioned medium, or tissues. The peptide's arginine/lysine-rich polybasic motif has itself been studied as a potential cell-penetrating and nuclear-localization element.

Several groups examined MGF in cardiac models. Stavropoulou and colleagues (2009) examined endogenous IGF-1Ea and MGF expression after artery-ligation-induced infarction in rats and characterized the synthetic 24-amino-acid E-peptide in H9c2 myocardial-like cells. Carpenter and colleagues (2008) used an ovine myocardial-infarction model, delivering mature IGF-1, the MGF E-domain, or full-length MGF intracoronarily and assessing cardiac function by echocardiography and infarct extent by histology. Mavrommatis, Shioura, Los, and Goldspink (2013) examined cellular uptake and nuclear localization of the synthetic 24-amino-acid E-domain in H9c2 cells and its relationship to the intrinsic apoptotic pathway; follow-up work delivered a D-arginine-stabilized, C-terminally amidated peptide by osmotic pump and encapsulated a labeled peptide in PEG-DMA microstructures as a delivery approach. Most recently, Solís and colleagues (2022) characterized how the phosphorylation state of a serine residue within the E-domain's 14-3-3 binding motif modulates 14-3-3γ and its interactions with contractile regulators such as cardiac myosin-binding protein C and phospholamban.

In neuronal models, Aperghis and colleagues (2004) examined two IGF-1 splice variants in a facial-motoneuron avulsion model. Dłużniewska and colleagues (2005) examined the synthetic C-terminal MGF peptide in a gerbil transient-brain-ischemia model and in organotypic hippocampal cultures, and probed the IGF-1R dependence of its activity, also noting endogenous MGF expression in ischemia-resistant hippocampal neurons. Riddoch-Contreras and colleagues (2009) delivered an MGF or IGF-1 cDNA expression plasmid into the hindlimb muscles of SOD1(G93A) mice at symptom onset and examined motor-unit and motoneuron survival. A later study (Tang and colleagues, 2017) examined MGF in the context of neurogenesis in the aging mouse brain.

Beyond muscle, MGF has been examined across connective-tissue and cancer-cell systems. Deng and colleagues (2011) examined the 24-amino-acid E-peptide in MC3T3-E1 osteoblast-like cells and a rabbit segmental bone-defect model, with MAPK-ERK and cell-cycle readouts; related work examined transcriptomic regulation of osteoblasts (Xin and colleagues, 2014) and microencapsulation for sustained delivery (Niu and colleagues, 2014). Schlegel and colleagues (2013) examined the splice variant in pig growth-plate cartilage, and tenocyte work (Zhang and colleagues, 2016) examined E-peptide effects on nuclear mechanics and chromatin. In cancer biology, Armakolas and colleagues (2010) examined preferential expression of the IGF-1Ec transcript in human prostate tissue, and Armakolas and colleagues (2015) examined the endogenously produced Ec peptide in PC-3 cells with ERK1/2 readouts and its association with epithelial-to-mesenchymal-transition markers and tumor staging. Structural and reagent work includes Philippou and colleagues (2008), who characterized a polyclonal antibody against the last 24 amino acids of the E-domain, and Vassilakos and colleagues (2014, 2016), who reviewed E-domain activity as addressed by synthetic peptides and used an anti-Ec antibody to identify endogenous E-peptides in tissues.

Across this literature the molecule actually studied varies — the endogenous IGF-1Ec/Eb splice variant, the synthetic free-acid 24-amino-acid E-peptide, D-arginine-stabilized and C-terminally amidated analogs, and PEGylated forms (PEG-MGF) — and findings are best attributed to the specific form examined rather than equated across forms. The human IGF-1Ec sequence also differs from the rodent IGF-1Eb sequence, so cross-species comparisons are made with care. Because the unmodified peptide is small and carries multiple basic residues, the literature notes a short circulating half-life, which motivates the stabilization and PEGylation chemistry studied as ways to slow proteolysis and extend circulation.